Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.76 - $13.06
Previous CloseN/A
Volume1.46M
Average Volume (3M)4.25M
Market Cap
$7.54B
Enterprise Value$3.85B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)1.9
Beta1.09
Next Earnings
Jun 25, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding713,549,440
10 Day Avg. Volume4,510,983
30 Day Avg. Volume4,254,660
Standard Deviation0.19
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)77.24
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.73
Enterprise Value/Ebitda0.87
Forecast
1Y Price Target
$44.00Price Target Upside312.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Financial PositionROIV has a very strong cash position and fundamentally de-risked pipeline programs.
Ownership IncreaseRoivant recently increased its ownership in Immunovant to ~57%, signaling confidence in the prospects of IMVT-1402.
Pipeline ProgressSolid progress on all fronts as its pipeline advances with multiple key data readouts.
Bears Say
EPS RevisionThe company revised FY25E EPS from -$0.67 to -$0.73.
Namilumab Study ResultsROIV announced that GM-CSF candidate namilumab failed to demonstrate treatment benefit in its Ph2 study in patients with pulmonary sarcoidosis, and the company will discontinue further development.
Revenue MissThe revenue miss was confounded by the sale of Dermavant which moved Vtama revenues to discontinued ops and contributed to a non-GAAP net loss of ($219M).
---
Ownership Overview
26.20% Insiders
12.78% Mutual Funds
42.26% Other Institutional Investors
4.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $9.76 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $7.54B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Jun 25, 2025 which is in 124 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Feb 10, 2025. The company reported -$0.203 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.05.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.25.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 713,549,440 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.203 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went down -0.918%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
---
Roivant Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (312.37% Upside)
$44.00 (312.37% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 16.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
-6.71%
12-Months-Change
Fundamentals
Return on Equity
-7.10%
Trailing 12-Months
Asset Growth
-20.79%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Roivant Sciences Ltd. discussed a strong financial position and a promising pipeline with several upcoming clinical milestones. However, the company faces challenges in ongoing litigation and a competitive landscape in certain areas.Read More>---
ROIV Stock 12 Month Forecast
Average Price Target
$44.00
▲(312.37% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Biohaven Ltd.
―
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+71.66%
reiterated a buy rating 9 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +71.66% per trade.
---